On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns about its Spine business. The analyst did not assign a price target following ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high ...

BTIG analysts have downgraded (NYSE:GMED) from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

According to InvestingPro data, the medical device manufacturer ... it was noted that while initial reactions to Globus Medical’s earnings call were optimistic, believing that the Spine business ...

Boston Scientific said it would halt worldwide sales of its Acurate devices due to “increased clinical and regulatory ...

A problem when preparing the devices for use can delay diagnosis or treatment, leading BD to update its instructions for use.

Zimmer Biomet announced today that it appointed Kevin Thornal as group president, global businesses and the Americas.